Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Akumin Inc AKUMQ

Akumin Inc. is a provider of radiology and oncology services to health systems, hospitals, physician groups, and patients all across the country. The Company operates through two segments: Radiology and Oncology. The Company provides fixed-site outpatient diagnostic imaging services through a network of approximately 180 owned and/or operated imaging locations, and outpatient radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 48 states. Its imaging procedures include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography and other related procedures. Its cancer care services include a full suite of radiation therapy and related offerings. Its services include radiology exams, radiology technology, radiology subspecialties, oncology conditions treated and oncology radiation therapy.


OTCPK:AKUMQ - Post by User

Comment by mjh9413on Aug 25, 2022 12:07am
252 Views
Post# 34918870

RE:There’s a ton of upside to Akumin (AKU), says Clarus

RE:There’s a ton of upside to Akumin (AKU), says ClarusI bought because I liked the idea the Alliance people were going to steer the Company but with Zine and Stonepeak  holding sway I am peeved. Zine gets a nice paycheck and other benefits while stonepeak reaps Millions$ in finance charges every qtr, the latter inflating the adj Ebitda number by 80%+. The latter wud have prevailed under any leadership but the existing group is just 'for the boys" as I see it and the Clarus numbers are blue-sky, even meaningless all in mho.For instance, on a profroma basis one wud have expected $750MM revs from the combined company. I cannot see how    AKU gets out of this ton of debt if EBDTA runs only about $20 to 25MM this year and possibly double that in 2023 at best..
Anyone got other numbers
<< Previous
Bullboard Posts
Next >>